| Multivalent antibodies: when design surpasses evolution ÁM Cuesta, N Sainz-Pastor, J Bonet, B Oliva, L Álvarez-Vallina Trends in biotechnology 28 (7), 355-362, 2010 | 308 | 2010 |
| Deep learning reveals cancer metastasis and therapeutic antibody targeting in the entire body C Pan, O Schoppe, A Parra-Damas, R Cai, MI Todorov, G Gondi, ... Cell 179 (7), 1661-1676. e19, 2019 | 186 | 2019 |
| Programming Controlled Adhesion of E. coli to Target Surfaces, Cells, and Tumors with Synthetic Adhesins C Piñero-Lambea, G Bodelón, R Fernández-Periáñez, AM Cuesta, ... ACS synthetic biology 4 (4), 463-473, 2015 | 178 | 2015 |
| A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity M Compte, SL Harwood, IG Muñoz, R Navarro, M Zonca, G Perez-Chacon, ... Nature communications 9 (1), 4809, 2018 | 130 | 2018 |
| Tumor immunotherapy using gene-modified human mesenchymal stem cells loaded into synthetic extracellular matrix scaffolds M Compte, ÁM Cuesta, D Sánchez-Martín, V Alonso-Camino, JL Vicario, ... Stem cells 27 (3), 753-760, 2009 | 117 | 2009 |
| Long-term in vivo imaging of human angiogenesis: critical role of bone marrow-derived mesenchymal stem cells for the generation of durable blood vessels L Sanz, P Santos-Valle, V Alonso-Camino, C Salas, A Serrano, JL Vicario, ... Microvascular research 75 (3), 308-314, 2008 | 99 | 2008 |
| Antibody engineering: facing new challenges in cancer therapy1 L Sanz, ÁM Cuesta, M Compte, L ÁLVAREZ‐VALLINA Acta Pharmacologica Sinica 26 (6), 641-648, 2005 | 81 | 2005 |
| Loss of PHD3 allows tumours to overcome hypoxic growth inhibition and sustain proliferation through EGFR AT Henze, BK Garvalov, S Seidel, AM Cuesta, M Ritter, A Filatova, F Foss, ... Nature communications 5 (1), 5582, 2014 | 80 | 2014 |
| Inhibition of tumor growth in vivo by in situ secretion of bispecific anti-CEA× anti-CD3 diabodies from lentivirally transduced human lymphocytes M Compte, B Blanco, F Serrano, ÁM Cuesta, L Sanz, A Bernad, P Holliger, ... Cancer gene therapy 14 (4), 380-388, 2007 | 80 | 2007 |
| In Vivo Tumor Targeting and Imaging with Engineered Trivalent Antibody Fragments Containing Collagen-Derived Sequences AM Cuesta, D Sánchez-Martín, L Sanz, J Bonet, M Compte, L Kremer, ... PLoS One 4 (4), e5381, 2009 | 78 | 2009 |
| EphrinB2 repression through ZEB2 mediates tumour invasion and anti-angiogenic resistance C Depner, H Zum Buttel, N Böğürcü, AM Cuesta, MR Aburto, S Seidel, ... Nature communications 7 (1), 12329, 2016 | 71 | 2016 |
| Enhanced antiangiogenic therapy with antibody‐collagen XVIII NC1 domain fusion proteins engineered to exploit matrix remodeling events VJ Sánchez‐Arévalo Lobo, ÁM Cuesta, L Sanz, M Compte, P García, ... International journal of cancer 119 (2), 455-462, 2006 | 49 | 2006 |
| The axonal repellent Slit2 inhibits pericyte migration: potential implications in angiogenesis I Guijarro-Munoz, AM Cuesta, A Alvarez-Cienfuegos, JG Geng, ... Experimental Cell Research 318 (4), 371-378, 2012 | 47 | 2012 |
| The multicompartmental p32/gClqR as a new target for antibody-based tumor targeting strategies D Sánchez-Martín, AM Cuesta, V Fogal, E Ruoslahti, L Alvarez-Vallina Journal of Biological Chemistry 286 (7), 5197-5203, 2011 | 45 | 2011 |
| PHD3 controls lung cancer metastasis and resistance to EGFR inhibitors through TGFα H Dopeso, HK Jiao, AM Cuesta, AT Henze, L Jurida, M Kracht, ... Cancer research 78 (7), 1805-1819, 2018 | 43 | 2018 |
| Intramolecular trimerization, a novel strategy for making multispecific antibodies with controlled orientation of the antigen binding domains A Alvarez-Cienfuegos, N Nuñez-Prado, M Compte, AM Cuesta, ... Scientific reports 6 (1), 28643, 2016 | 41 | 2016 |
| Proteasome activator complex PA28 identified as an accessible target in prostate cancer by in vivo selection of human antibodies D Sánchez-Martín, J Martínez-Torrecuadrada, T Teesalu, KN Sugahara, ... Proceedings of the National Academy of Sciences 110 (34), 13791-13796, 2013 | 40 | 2013 |
| Differential transplantability of human endothelial cells in colorectal cancer and renal cell carcinoma primary xenografts L Sanz, AM Cuesta, C Salas, C Corbacho, C Bellas, L Alvarez-Vallina Laboratory investigation 89 (1), 91-97, 2009 | 39 | 2009 |
| Factory neovessels: engineered human blood vessels secreting therapeutic proteins as a new drug delivery system M Compte, V Alonso-Camino, P Santos-Valle, ÁM Cuesta, ... Gene therapy 17 (6), 745-751, 2010 | 33 | 2010 |
| The β2-adrenergic receptor antagonist ICI-118,551 blocks the constitutively activated HIF signalling in hemangioblastomas from von Hippel-Lindau disease AM Cuesta, V Albiñana, E Gallardo-Vara, L Recio-Poveda, I De Rojas-P, ... Scientific Reports 9 (1), 10062, 2019 | 30 | 2019 |
